Table 2
Characteristics of patients with short segment Barrett's oesophagus (SSBO) and dysplasia
| Patient no | Age/Sex | Length of SSBO (cm) | Grade of dysplasia | Total follow up (months) | Medical treatment | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial | First detection | Most recent | |||||||||
| 1 | 75/M | 2 | ND | HGD | Cancer | 33 | H2RA | ||||
| 2 | 54/M | 2 | ND | HGD | LGD | 32 | H2RA | ||||
| 3 | 69/M | 1 | ND | LGD | ND | 36 | Omeprazole | ||||
| 4 | 70/M | 2 | ND | LGD | ND | 67 | Omeprazole | ||||
| 5 | 61/M | 2 | ND | LGD | ND | 36 | None | ||||
| 6 | 61/M | 1 | LGD | LGD | ND | 8 | H2RA | ||||
| 7 | 47/M | 1.5 | LGD | LGD | ND | 100 | Omeprazole | ||||
| 8 | 72/M | 2 | LGD | LGD | ND | 86 | Omeprazole | ||||
| 9 | 67/M | 2 | LGD | LGD | ND | 41 | Omeprazole | ||||
| 10 | 56/M | 2 | ND | LGD | LGD | 14 | Omeprazole | ||||
| 11 | 72/M | 2 | LGD | LGD | ND | 54 | Omeprazole | ||||
| 12 | 44/M | 1 | HGD | HGD | ND | 1 | Lansoprazole | ||||
| 13 | 70/M | 1 | ND | LGD | LGD | 11 | H2RA | ||||
| 14 | 53/M | 1 | LGD | LGD | LGD | 2 | Lansoprazole | ||||
| 15 | 50/M | 1 | LGD | LGD | ND | 15 | Lansoprazole | ||||
| 16 | 67/M | 2 | ND | LGD | ND | 18 | Lansoprazole | ||||
| 17 | 50/M | 1 | LGD | LGD | LGD | 3 | Lansoprazole | ||||
| 18 | 76/M | 1 | LGD | LGD | ND | 60 | H2RA | ||||
| 19 | 55/M | 1 | LGD | LGD | ND | 2 | H2RA | ||||
| 20 | 68/M | 2 | ND | HGD | LGD | 62 | Omeprazole | ||||
| 21 | 76/M | 1 | LGD | LGD | ND | 3 | H2RA | ||||
| 22 | 58/M | 1 | LGD | LGD | LGD | 1 | H2RA | ||||
| 23 | 68/M | 1 | LGD | LGD | ND | 49 | H2RA | ||||
| 24 | 49/M | 1 | HGD | ND | ND | 12 | H2RA | ||||
| 25 | 57/M | 1 | ND | LGD | ND | 8 | H2RA | ||||
-
H2RA, H2 receptor antagonist; ND, no dysplasia; HGD, high grade dysplasia; LGD, low grade dysplasia.
